Scientific Publications by FDA Staff
J Pharm Sci 2013 May;102(5):1513-23
Process analytical technology to understand the disintegration behavior of alendronate sodium tablets.
Xu X, Gupta A, Sayeed VA, Khan MA
Various adverse events including esophagus irritations have been reported with the use of alendronate tablets, likely attributed to the rapid tablet disintegration in the mouth or esophagus. Accordingly, the disintegration of six alendronate tablet drug products was studied using a newly developed testing device equipped with in-line sensors, in addition to the official compendial procedure for measuring the disintegration time. The in-line sensors were used to monitor the particle count and solution pH change to assess the onset and duration of disintegration. A relatively large variation was observed in the disintegration time of the tested drug products using the compendial method. The data collected using the in-line sensors suggested that all tested drug products exhibited almost instantaneous onset of disintegration, under 2 s, and a sharp drop in solution pH. The drop in pH was slower for tablets with slower disintegration. The in-house prepared alendronate test tablets also showed similar trends suggesting rapid solubilization of the drug contributed to the fast tablet disintegration. This research highlights the usefulness of the newly developed in-line analytical method in combination with the compendial method in providing a better understanding of the disintegration and the accompanying drug solubilization processes for fast disintegrating tablet drug products.
|Category: Journal Article|
|PubMed ID: #23450666||DOI: 10.1002/jps.23488|
|Includes FDA Authors from Scientific Area(s): Drugs|
|Entry Created: 2013-03-02||Entry Last Modified: 2016-03-21|